← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06080100

RELIEF OF PSYCHOEMOTIONAL STRESS USING XENON SEDATION

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Psychological Stress
Sponsor The S.N. Fyodorov Eye Microsurgery State Institution
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 140
Sex ALL
Min Age 18 Years
Max Age 45 Years
Start Date 2023-11-01
Completion 2026-01-01
Interventions
Xenonpremedication hydroxyzine 25 mg

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to propose for implementation and evaluate the effectiveness of xenon sedation for the relief of psychoemotional stress disorder before the operation of refractive laser vision correction patients with high anxiety and stress instability who underwent xenon analgosedation before refractive laser vision correction. The main question\[s\] it aims to answer are: 1. To develop a method of xenon sedation in patients with a high level of psychoemotional stress before surgery - refractive laser vision correction. 2. To evaluate the effect of inhaled xenon anesthesia in a sub-narcotic dose on the duration of surgery, satisfaction of surgeons and patients with anesthesia, the level of postoperative pain in patients in comparison with anxiolytics. The following will be studied: the level of preoperative anxiety, the dynamics of glycemia and blood cortisol levels, heart rate variability, electrical microamplitudes of the ECG signal, the anti-stress and analgesic effect of xenon. If there is a comparison group: the researchers will compare \[the group with xenon sedation and the control group\] to see if there is \[an anti-stress effect of xenon in patients before laser vision correction\].

Eligibility Criteria

Inclusion Criteria: * upcoming operation ReLEx® SMILE; * high anxiety and stress instability (Spielberger-Khanin test of 46 points or more); * signed informed consent to participate in the study. Exclusion Criteria: \- concomitant somatic diseases in the decompensation stage.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}